BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31277685)

  • 1. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
    Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
    Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM; Grothey A
    Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
    Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
    Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway.
    Li Z; Chen Y; An T; Liu P; Zhu J; Yang H; Zhang W; Dong T; Jiang J; Zhang Y; Jiang M; Yang X
    J Exp Clin Cancer Res; 2019 Mar; 38(1):139. PubMed ID: 30922391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
    Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
    Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
    Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
    Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
    Sai K; Wang S; Balasubramaniyan V; Conrad C; Lang FF; Aldape K; Szymanski S; Fokt I; Dasgupta A; Madden T; Guan S; Chen Z; Alfred Yung WK; Priebe W; Colman H
    J Neurooncol; 2012 May; 107(3):487-501. PubMed ID: 22249692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X; Wei Y; Wei X
    Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H; Clamor C; Müller K
    J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus infection promotes the formation of glioma stem cells from glioblastoma cells through the TLR9/NEAT1/STAT3 pathway.
    Zang J; Zheng MH; Cao XL; Zhang YZ; Zhang YF; Gao XY; Cao Y; Shi M; Han H; Liang L
    Cell Commun Signal; 2020 Aug; 18(1):135. PubMed ID: 32843056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
    Jonker DJ; Nott L; Yoshino T; Gill S; Shapiro J; Ohtsu A; Zalcberg J; Vickers MM; Wei AC; Gao Y; Tebbutt NC; Markman B; Price T; Esaki T; Koski S; Hitron M; Li W; Li Y; Magoski NM; Li CJ; Simes J; Tu D; O'Callaghan CJ
    Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):263-270. PubMed ID: 29397354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential
    Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
    Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
    J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
    Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
    Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells.
    Wu N; Liu J; Zhao X; Yan Z; Jiang B; Wang L; Cao S; Shi D; Lin X
    Tumour Biol; 2015 Dec; 36(12):9667-76. PubMed ID: 26150336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
    Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
    BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.